Peter Whang , M.D. –Yale School of Medicine - Prevalence, education and treatment of SI joint dysfunction
Bharat Desai , M.D. – Panorama Orthopedics & Spine Center- Sacroiliac joint fusion in trauma and the role of telehealth
William Tobler , M.D. –Mayfield Clinic - Spino-pelvic procedures migrating to ASCs
- Why iFuse is a good fit for sacroiliac fusions at ASCs
Robert Eastlack , M.D. –Scripps Health - Biomechanical and clinical evidence for long constructs, including the ISSG and SILVIA studies
- Biomechanical and clinical evidence for long constructs, including the ISSG and SILVIA studies
Interested parties may register for the event by clicking HERE or by visiting SI-BONE’s Events page on the investor relations website at https://investor.si-bone.com/events.
About
The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. The iFuse Implant System is also intended for sacroiliac fusion to augment stabilization and immobilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion. In addition, the iFuse Implant System is intended for sacroiliac fusion in acute, non-acute, and non-traumatic fractures involving the sacroiliac joint. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit.
Media Contact:
jpowers@si-bone.com
669-206-2521
Investor Contacts:
investors@SI-BONE.com
Source: SI-BONE, Inc.